Core Viewpoint - Bayer has received its first domestic medical device registration certificate for its MEDRAD Stellant D-CE high-pressure injection system and accessories, marking a significant step in localizing production in China [1][3]. Group 1: Bayer's Localization Efforts - Bayer's MEDRAD Stellant D-CE high-pressure injection system is designed for intravenous injection of contrast agents in diagnostic imaging, including CT and mammography [3]. - The registration inspection cycle for Bayer's first domestically produced medical device was shortened to 1.5 months, significantly accelerating the product's market entry [3]. - Bayer's first manufacturing facility for imaging diagnostic devices in China was established in Beijing Economic Development Zone in September 2023 [4]. Group 2: Industry Trends - Many foreign companies are increasing their local production efforts in China, with notable examples including Illumina and Terumo, which have announced plans for localized manufacturing of high-end medical devices [4]. - The Chinese medical device market has shown substantial growth, with revenues increasing from 553.2 billion yuan in 2014 to 1.31 trillion yuan in 2023, reflecting a compound annual growth rate of 10% [6]. - China is projected to become the largest medical device market globally by 2030, indicating significant future growth potential [7]. Group 3: Policy Support - Recent policies have been favorable for foreign enterprises, encouraging them to localize production of innovative pharmaceuticals and high-end medical equipment [8]. - The Chinese government has implemented measures to simplify the registration process for imported medical devices produced domestically, enhancing the ease of market entry for foreign companies [7][8]. - A proposed government procurement policy suggests a 20% price deduction for domestic products in competitive bidding, further incentivizing local production [9].

导读： 在全球布局生产线的仪器品牌在此次突发的关税事件中受到的影响相对较小，更具主动权。基于此，仪器信息网特别对美国仪器品牌全球生产 线分布情况进行统计，供广大读者参考。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近期，全球关税大战呈现愈演愈烈之势，从"对等关税"到"极限施压"，新一轮威胁对市场带来了巨大的不确定性。 2 0 2 5年4月2日，美国声称中方"未履行贸易承诺"，对中国商品加征3 4%关税，累计税率达5 4%；4月7日，特朗普再度加征5 0%关 税，总税率飙升至1 0 4%。 4月4日，中国采取多项反制措施，其中一项是对原产于美国的所有进口商品，加征3 4%关税；4月9日，中国再次采取系列强硬反制 措施，并 宣布对原产于美国的所有进口商品的加征关税税率由3 4%提高至8 4% 。 作为全球高端仪器设备的核心供给国，美国在质谱仪、核磁共振仪、半导体制造设备等领域长期占据技术主导地位（全球市场份额 超6 0%），而中国仪器行业对美进口依赖度高达3 2%。美国关税政策与中国反制举措形成的关税大战，将不可避免地直接冲击美国 ...